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ABSTRACT
Background: Sclerostin, a soluble canonical Wingless integration site
signaling inhibitor, is formed by osteocytes and is vital for bone physiology.
This work aimed to appraise the role of sclerostin level in early detection of
renal osteodystrophy in patients with type 2 diabetes mellitus (T2DM).
Method: This cross sectional study was done on 75 diabetic patients with
different stages of chronic kidney disease (CKD) in the Internal Medicine
department, Zagazig University hospital.The patients are classified into 3
groups according to glomerular filtration rate(GFR),group 1(stage 1,2
CKD),group 2(stage 3 CKD),group 3(stage 4,5 CKD). The patients
underwent history taking, examination and laboratory studies including
routine investigations and assessment of serum sclerostin. Results: The mean
age of the patients was 51.07 ± 4.40 years. Males represented 61.3% of them.
Mean Sclerostin of them was 5.42 ± 4.53 ng/ml. There are significant
differences between groups with different CKD stages regarding sclerostin,
hemoglobin, serum creatinine, blood urea, eGFR, phosphorus and parathyroid
hormone. There is significant positive correlation between serum sclerostin
and all of serum creatinine, blood urea, phosphorus and parathyroid hormone.
There is significant negative correlation between it and eGFR. On
multivariate regression analysis, it was found that age, serum creatinine,
blood urea, eGFR and albumin/creatinine ratio (ACR) significantly associated
with serum level. Conclusion: Sclerostin level is negatively correlated with
eGFR in diabetic patients with impaired renal function. Serum sclerostin
levels increase in diabetic patients starting from CKD-G3 stage. Age, serum
creatinine, blood urea, eGFR and albumin/creatinine ratio (ACR)
significantly associated with its level.
Keywords: Chronic kidney disease; Diabetes; sclerostin

INTRODUCTION
iabetes mellitus is a group of metabolic
ailments characterized by hyperglycemia
originating from imperfection in insulin
secretion, action or both. The chronic diabetic
hyperglycemia is connected with long dated

D
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impairment, dysfunction and failure of other
organs particularly the eyes, kidneys, nerves
and blood vessels1.
CKD is defined as impairments of
kidney function or construction existing for
more than 3 months, with health consequences.
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This definition covers patients with a
glomerular filtration rate (GFR) of < 60
ml/min/1.73 m2 on at least 2 instances parted by
a period of at least 90 days (with or without
kidney damage marker). The risk of developing
CKD surges with age. With advancement in
kidney dysfunction, some simultaneous
conditions get commoner and rise in severity.
Finally, it can evolute to end-stage kidney
disease(2).
The prevalence of end-stage renal
disease (ESRD) tend to rise, although the
incidence has stabilized (3).
Metabolic bone disorders in CKD are
the consequences of changed mineral and bone
metabolism (MBD) due to compromised renal
function (4).
Bone biopsy is still the gold standard
test aimed at categorizing renal osteodystrophy
(RO) though more rarely done. The bone
turnover rate measured by cycline double
labeling and the osteoid thickness are the chief
parameters that outline RO forms(5).
Sclerostin and Dickkopf-1 (Dkk-1),
Wingless integration site (Wnt) inhibitors that
decrease bone formation, may play a role in
CKD related bone disorders. It can clarify the
low bone creation detected in some uremic
forms6
Basal serum sclerostin level, a marker
of bone resorption, is a worthy predictor of
bone loss in CKD patients as evaluateded by
DEXA or QCT5. Overall, those biomarkers can
mirror the bone disease severity7
This work aimed to appraise the role of
sclerostin level in early detection of renal
osteodystrophy ―bone mineral disease‖ in
patients with type 2 diabetes
Patient and Methods
The work has been carried in accordance with
The Code of Ethics of the World Medical
Association (Declaration of Helsiniki) for
studies involving humans. A written informed
consent was handled from the patient to
contribute in the study. Approval for execution
the research was gotten from Internal Medicine
and Medical Biochemistry Departments,
Mahmoud H., et al…
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Zagazig University Hospitals after receiving
Institutional Review Board (IRB) approval.
Study Design, Study Setting, and Study
Participants
A cross-sectional study was conducted in
Internal Medicine department at Zagazig
University through the period of September
2018 to February 2019. This study included 75
T2DM patients with CKD who visited the
endocrinology or nephrology clinic.
Sample size:
Assuming that mean±SD of serum sclerostin
level in G1,2 CKD versus G3 CKD is 54.6±6.9
vs 60±9.2, the sample was calculated to be 75
patients using OPEN-EPI with power 80% and
confidence interval 95%. The patients were
selected by systematic random technique
Inclusion criteria
Ages from 35 to 65 year
Normal liver function
Duration of diabetes more than 5 years
Exclusion criteria
Other chronic diseases
Well-known syndromes affecting bone
Previous or current treatment with drugs
distressing bone metabolism.
Study Assessments and Data Collection
For each eligible patient, we reported the
following data:
History
Detailed history taking include name, age, sex,
special habits, associated comorbidities,
diabetes mellitus index (duration, type,
medication).
Full general examination and Staging of CKD
CKD is classified into 5 stages. This
classification uses the combination of an index
of kidney function, GFR, and markers of
kidney damage to define the stages. Stages 3–
5(stage 3:GFR 30 to 59,stage 4:GFR 15 to
29,stage 5:GFR less than 15) were defined by a
GFR less than 60 ml/min/1.73 m2 with or
without markers of kidney damage, on at least 2
separate occasions separated by a period of at
least 90 days. Stages 1 and 2(stage 1:GFR more
than 90 ml/min/1.73 m2,stage 2:GFR 60 to 89
ml/min/1.73 m2) were defined by the presence
59 | P a g e
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of markers of kidney damage including
albuminuria, urine sediment abnormalities,
electrolyte and other abnormalities caused by
tubular disorders, abnormalities detected by
histology and structural abnormalities detected
by imaging (8).
Laboratory investigations:
Venous blood samples were withdrawn in the
morning following overnight fasting. Sera were
stored at −80∘C until examination. The routine
laboratory investigations were done according
to Clinical Pathology department and
laboratories of Zagazig University Hospitals’
protocol and include:
Complete blood count (CBC): measured by
automated blood counter (by sysmex XN
2000).
Kidney function tests: serum creatinine, serum
urea and uric acid by colorimetric assay (by
cobas 8000 series module C 702).
Liver function tests: serum albumin, total
protein, bilirubin, AST and ALT by
colorimetric assay (by cobas 8000 series
module C 702).
Calcium and phosphorous (by cobas 8000
series module C 702).
PTH (by cobas 6000 series module e 601)
Estimated glomerular filtration rate (eGFR)
using MDRD equation: eGFR = 175 x (Cr)-1.154
x (Age)-0.203 x (0.742 if female) x (1.210 if
black)
Albumin creatinine ratio (ACR) (by cobas
6000 module C 501).
Random blood Sugar (by cobas 8000 series
module C 702).
HbA1c (by cobas 6000 module C 501).
CRP (by cobas 8000 series module C 702).
Serum sclerostin level was assessed using
enzyme-linked immune sorbent assay (ELISA).
The assay was carried out by Human Sclerostin
(SOST)
ELISA
Kit
by
AndyGene
Biotechnology Co., LTD, Shanghai
Statistical Analysis
All data were gathereed, tabulated and
statistically analyzed using SPSS 20.0 for
windows (SPSS Inc., Chicago, IL, USA) &
MedCalc 13 for windows (MedCalc Software
Mahmoud H., et al…
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bvba, Ostend, Belgium). Data were tested for
normal distribution using the Shapiro Walk test.
Qualitative data were symbolized as
frequencies and relative percentages. Chi
square test (χ2) was used to compute difference
between qualitative variables. Quantitative data
were stated as mean ± SD (Standard deviation).
Mann Whitney test was used to compare
medians of two groups (for nonparametric
data).One way ANOVA test was used to
compare between more than two dependent
groups of normally distributed variables while
Kruskal Wallis test ranks test was used for nonnormally distributed variables. Pearson’s and
Spearman correlation tests were used for
correlating
normal
and
non-parametric
variables respectively. Multivariate regression
analysis (stepwise method) was performed to
ascertain factors associated with sclerostin
levels. All statistical comparisons were two
tailed with significance Level of P-value ≤ 0.05
is significant and p ≤0.001 is highly significant
difference.
RESULTS
The present study comprised 75 patients with
diabetes. Their mean age of 51.07 ± 4.40 years.
The largest percentage of the studied patients
were male (61.3%), about 47% of them had
comorbid hypertension and 18.7% of them had
history of ischemic heart disease. The baseline
characteristics were reported in (Table 1).
Mean Sclerostin of the studied patients was
5.42 ± 4.53 ng/ml ranging from 0.097 – 22.04
ng/ml. There is a statistically significant
relation between the studied groups with
different stages of CKD and sclerostin level.
Highest level was among patients with stage 5.
However, there is non-significant relation
between gender and serum sclerostin level
(Table 2).
There is statistically significant difference
between patients with different CKD stages
regarding hemoglobin level which was lower in
patients with grade 5 as found in post hoc test
(Table 3)
There is statistically significant difference
between patients with different CKD stages
60 | P a g e
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regarding serum creatinine, blood urea levels,
eGFR, Po4 and parathyroid hormone level. On
doing posthoc test, the difference is significant
patients with stage 5 and each other group
regarding serum creatinine and eGFR while the
difference is significant between each two
groups regarding PTH and phosphorus. The
group of stage 1 CKD ahd the lowest blood
urea level (Table 3)
On the other hand, there is no difference
between patients with stages of CKD regarding
demographic characteristics, TLC, platelet
count, liver function test, random blood sugar,
HbA1c, ACR, serum calcium or CRP (Table 3)

There is significant positive correlation
between serum sclerostin and all of serum
creatinine, blood urea, Po4 and serum
parathyroid hormone. There is also significant
yet negative correlation between it and eGFR.
On the other hand, there is non-significant
correlation between serum sclerostin and other
studied parameters (Table 4).
On multivariate regression analysis of factors
independently associated with serum sclerostin,
it was found that age, serum creatinine, blood
urea, eGFR and ACR found to be significantly
associated with serum level (Table 5).

Table 1. Demographic data and comorbidities of all patients
All patients
(n=75)
Age(years)
Mean ± SD
Range
Sex

51.07 ± 4.40
43 - 59
Male

46 (61.3%)

Female

29 (38.7%)

HTN
IHD

35 (46.7%)
(Male:20) (Female:15)
14 (18.7%)
(Male:8) (Female:6)

IHD ischemic heart disease HTN hypertension

Table 2. Serum sclerostin of all patients and distribution according to grades of
Nephropathy
P
test
Stage 5
Stage 4
Stage 3
Stage 2
Stage 1
Variable
(n=8)
(n=20)
(n=22)
(n=18)
(n=7)
15.18±3.17
7.18 ± 1.55 3.86 ±0.75 1.52±0.6 0.14 ± 0.06
Sclerostin
0.001 37.61
6
p
Total
Females
Males
Variable
(n=29)
(n=46)
0.638
5.42 ± 4.53 5.07 ± 4.12
5.62 ± 3.65
Sclerostin(ng/mL)
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Table 3. Comparison between patients according to GFR stages regarding demographic and laboratory
characetristics
Variable
Stage 1
Stage 2
Stage 3
Stage 4
Stage 5
Test
P
(n=7)
(n=18)
(n=22)
(n=20)
(n=8)
Mean±
Mean±
Mean±
Mean±
Mean±
SD
SD
SD
SD
SD
Demographic criteria
Age (years)

52.2 ±
4.17

50.6 ±
4.47

50.5±
4.72

52.0±
4.39

0.75

0.53

5(71.4%
)
Female 2(28.6%
)
BMI
28.1 ±
2.24
CBC

8
(44.4%)
10
(55.6%)
26.5 ±
1.79

15
(68.2%)
7
(31.8%)
27.2 ±
1.51

11(55%)

7(87.5%)

4.175

0.084

9(45%)

1(12.5%)

26.4 ±
1.71

25.4 ±
2.53

2.015

0.12

Hemoglobin

12.25 ±0
.59
7.13 ±
1.25
284.8±79
.9

11.5 ±
.89
6.96 ±
1.56
274.7±7
4.2

11.49 ±
.87
7.12 ±
1.63
277.1±7
8.8

9.45±0.5
9
7.02±1.72

3.96

0.012

0.065

0.98

273.2±77.
09

0.087

0.97

0.86
±0.16
0.16
±0.07
4.32
±0.55
7.02
±0.53
17.9 ±
5.74
27.75 ±
7.09

0.87 ±
0.19
0.15 ±
0.05
4.33 ±
0.55
7.0 ±
0.49
18.4 ±
6.28
28.6 ±
7.29

0.86 ±
0.21
0.14
±0.06
4.21 ±
0.49
6.97 ±
0.51
17.67 ±
5.7
28.05 ±
6.99

0.91±0.17

0.061

0.98

0.16±0.07

0.27

0.85

4.07±0.75

0.035

0.99

6.85±0.30

0.046

0.98

19.23±4.6
5
31.13±8.4
6

0.34

0.79

0.49

0.69

226.6±18
.8
6.88 ±
0.28

226.4±1
7.9
6.91 ±
0.28

224.5±1
7.9
6.89
±0.27

243.3±10.
32
6.81±0.26

0.059

0.91

0.35

0.79

152.9±13

202.5±9

167.9±

119.4±11

0.71

0.55

Se
x

46.6 ±
5.13

Male

11.9 ±0
.65
TLC
7.14 ±
2.07
Platelet
269.4±8
count
5.1
Liver functions
T. Bilirubin

0.90 ±
0.28
D. bilirubin
0.16 ±
0.04
Albumin
4.38
±0.59
Total
6.94
protein
±0.34
AST
20.6 ±
8.53
ALT
32.0 ±
7.94
Diabetic follow up
RBS

225.8±1
5.7
HbA1c
7.02 ±
0.29
Kidney function
ACR

173.6±9
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2.9

Creatinine

0.86 ±
0.975 ±
.114
.141
Urea
37.2 ±
32.2 ±
6.34
6.73
eGFR
98.5 ±
77.1 ±
6.78
7.24
Mineral and parathyroid profile
Phosphorus

3.38 ±
0.46
Parathromo
34.4 ±
ne
15.3
Calcium
9.10 ±0
.42
CRP
5.80 ±
1.64
TLC total leucocytic count

3.87 ±
0.67
63.4 ±
27.6
8.96 ±
0.43
6.75 ±
1.65

7.3

127.6

0.2

1.76
±0.19
62.7 ±
7.08
40.2 ±
5.35

2.93 ±0
.21
98.8 ±
7.14
21.6 ±
3.29

4.60±0.63

46.19

<0.001

99.10±6.9
4
12.69±1.2
2

38.36

<0.001

49.21

<0.001

4.02 ±
0.72
84.8 ±
30.2
8.96 ±
0.40
6.56 ±
1.66

4.63 ±
0.85
169.8 ±
69.9
8.82 ±
0.59
6.52 ±
1.75

5.69±1.23

12.07

<0.001

413.6±30
6.1
8.39±0.69

19.85

<0.001

0.82

0.13

6.7±1.38

0.43

0.73

eGFR estimated glomerular filtration rate, ACR: albumin creatinine ratio, PTH:
parathyroid hormone p<0.05 is statistically significant HbA1c: glycosylated hemoglobin BMI: body mass index

Table 4. Correlation of Sclerostin with other parameters
Sclerostin
r
Age

BMI

Hemoglobin

TLC

Platelet

ACR

T. Bilirubin

D. Bilirubin

0.120

p

0.317

r

-0.138

p

0.249

r

0.077

p

0.526

r

0.002

p

0.985

r

0.041

p

0.733

r

-0.126

p

0.294

r

0.083

p

0.491

r

0.129

Mahmoud H., et al…
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Albumin

Total protein

AST

ALT

Random blood sugar

HbA1C

CRP

Calcium

Creatinine

Urea

eGFR

Phosphorus

Parathromone

10.21608/zumj.2020.16472.1477

p

0.284

r

-0.077

p

0.523

r

-0.081

p

0.502

r

0.131

p

0.276

r

-0.205

p

0.087

r

0.114

p

0.344

r

0.002

p

0.986

r

0.093

p

0.440

r

-0.254

p

0.196

r

0.895

p

< 0.001

r

0.759

p

< 0.001

r

-0.786

p

< 0.001

r

0.584

p

< 0.001

r

0.662

p

< 0.001

r correlation coefficient SE standard error of mean eGFR estimated glomerular filtration rate, ACR: albumin
creatinine ratio, PTH: parathyroid hormone p<0.05 is statistically significant HbA1c: glycosylated hemoglobin
BMI: body mass index
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Table 5. Multivariate regression analysis to identify factors influencing sclerostin levels
Unstandardized
Standardized
p
95.0% Confidence Interval
Coefficients
Coefficients
for β
β
S.E
β
Lower
Upper Bound
Bound
-.554
.363
-.136
.133
-1.283
.175
Hemoglobin
Phosphorus

-.213

.484

-.041

.661

-1.183

.757

PTH

-.055

.029

-.212

.061

-.112

.003

Age

-.082

.064

-.107

.027

-.212

.047

Creatinine

3.787

1.449

.900

.012

.882

6.692

Urea

.004

.039

.035

.029

-.083

.074

eGFR

-.014

.024

-.105

.007

-.034

.062

ACR

.004

.002

.121

.044

-.001

.008

SE standard error of mean eGFR estimated glomerular filtration rate, ACR: albumin creatinine ratio, PTH:
parathyroid hormone p<0.05 is statistically significant

Age, creatinine, urea, eGFR and ACR found to be significantly associated with sclerostin levels.
DISCUSSION
Sclerostin, a glycoprotein which is produced
almost only by osteocytes. It negatively
regulates bone production by tying to lowdensity lipoprotein receptor-related proteins
(LRPs) 5/6 and by antagonizing the Wntcatenin signaling pathway. Wnt/β-catenin
signaling pathway is a molecular trail
recognized to be critical bone mineral
physiology regulation. Wnt ligands fix to LRP
5/6 membrane receptor complex ending in
increasing bone formation9.
The effect of wnt signaling on bone is
facilitated by probing stem cell and
preosteoblast multiplicationg, induction of
osteoblastogenesis, and stopping osteoblast and
osteocyte apoptosis 10.
In healthy subjects, circulating sclerostin
concentration has been described to be greater
in males. Sclerostin level positively correlates
with age, BMI, and BMD. Serum sclerostin
level increase with advanced age and in
subjects with high BMI and high BMD11.
To the best of our knowledge, there are few
studies in the literarture that revealed the
association of serum sclerstin levels in with
Mahmoud H., et al…
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different liver and kidney fuctions tests in CKD
patients. Serum sclerostin level increase with
deterioration of liver and kidney functions.
In our study, as regarding the demographic
data, the mean age of the studied subjects was
51.07 ± 4.40 years and among them there were
46 males and 29 females.
This came opposite to Kim et al. (12) who
evaluated serum sclerostin level reagrding renal
function in T2DM patients and the mean age
within their study was higher (67.4 ± 7.3 years).
Male and female distribution (143 males and
159 females) that was inverse to our results.
There is no statistical significant difference
between studied groups\with different CKD
stages regarding the age or random blood sugar.
In the current study, the mean value of
sclerostin was 5.42 ± 4.53 ng/ml. Kim et al. (12)
found that median sclerostin level in their
patients was 28.66 ng/ml.
There was a highly significant difference in
sclerotin serum levels between the different
CKD subgroups, being higher in G5 group.
This agreed with the results of Cejka et al. (13)
who found that patients CKD, stage 5 on
dialysis had higher sclerostin levels and
65 | P a g e
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submitted that raised up sclerostin has a role in
ROD. They stated that sclerostinhad a
significant negative association with bone
turnover parameters.
This also came in consistent with another study
who showed that sclerostin was significantly
rising in patients with G4/5 or G3 after
adjusting for age, sex, and BMI (225.5 ± 10.9
versus 84.9 ± 9.2 versus 54.6 ± 6.9 pmol/l)(12).
Our study showed that there is a significant
difference between the GFR groups regarding
hemoglobin,
creatinine,
urea,
eGFR,
phosphorus, PTH and sclerostin.
Sabbagh et al. (14) conveyed that osteocytes
suppression Wnt-catenin signaling and higher
expression of sclerostin happened in early stage
of CKD in a genetic model of mice. They
advocated that subjugation of the Wnt-catenin
pathway is an early incident in the evolution of
ROD.
Cejka et al. (13) found that higher sclerostin in
CKD patients were not owing to diminished
renal
excretion.
However,
augmented
circulating sclerostin is due increased sclerostin
formation in uremic patients.
Our study showed that there is a significant
positive correlation between sclerostin with
creatinine, urea, ACR, phosphorus and PTH
and a negative correlation with age, BMI,
hemoglobin, eGFR and calcium.
In this study, there was a positive correlation
between age and serum sclerostin levelsin
agreement with other studies (15-16).
Serum sclerostin level upsurges considerably
with age in healthy pre and postmenopausal
females. Serum sclerostin rises over life by
about 3.7-fold. Raising sclerostin formation by
osteocytes may be tangled in the age-related
deficiency of bone formation (17).
Elderly patients have strikingly diminished
renal function. The positive relationship
between sclerostin and age could be originating
from renal impairment, which is not precisely
evaluated in other diseases. Osteoporosis in
elderly may partially result from rising
sclerostin owing to an undervalued renal
impairment.
Mahmoud H., et al…
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We found a highly significant negative
correlation between the serum sclerostin levels
and eGFR.
This came in accordance with Cejka et al. (13)
who revealed that renal sclerostin excretion up
rises with diminishing renal function. Both
relative and absolute sclerostin levels
eliminated by the kidneys rise with declining
eGFR.
We reported that increased serum levels are
thanks to higher sclerostin formation in uremic
patients, as has been submitted by Sabbagh et
al. (15).
The current study came in consistent with
Pelletier et al. (14) who found that serum
sclerostin levels rises as eGFR reduced in CKD
patients. Still, it was unidentified whether this
result relates to the patients with T2DM.
The core mechanisms of higher levels of
sclerostin in ckD are unknown. PTH receptor
signaling is a recognized sclerostin expression
inhibitor. As uremia causes PTH opposition,
reducing PTH signaling activity might end in
increased fabrication of sclerostin in CKD
patients (14).
In the current study, a highly significant
positive correlation between the serum
sclerostin levels and PTH levels was detected.
This came in harmony with Kim et al. (12) who
reported a positive correlation between
sclerostin and PTH in patients with CKD-G3-5.
Our results disagreed with the results of many
studies that have shown inverse correlation
between serum sclerostin and PTH level
(13,15,18)
.
Contradictory results were also reported by
Thambiah et al. (19) have shown reverse
correlation between serum sclerostin and PTH
level. Mirza et al. (20) stated that sclerostin
levels inversely correlated with PTH in
postmenopausal women short of CKD.
The discrepancy of the results could be
attributed to that renal failure ends in skeletal
resistance to PTH, and reducings in PTH
signaling activity might result in increased
production of sclerostin in CKD patients. The
actions of PTH on bone are mediated, at least
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partly, through decreasing of sclerostin
expression (18).
There was a positive correlation between the
serum sclerostin levels and serum phosphorous
levels in our patients.
Additional study reported that serum phosphate
was independently associated with sclerostin
(15)
.
Similarly, this came in accordance with
Ferreira et al. (21) as they reported that dietary
phosphate motivated bone sclerostin expression
irrespective of PTH in a model of CKDadynamic bone disease.
We partially settled with Kim et al. (12) where
there was a weak correlation between serum
phosphate and sclerostin.
This proposes that increases in phosphorus and
sclerostin levels in CKD patients happened
simultaneously but are not essentially
mechanistically related (6).
Hwever, Cejka et al. (13) stated that there was
no relation between serum sclerostin and
fractional excretion of phosphate.
By the multivariate analysis, the correlation
between serum phosphorous and serum
sclerostin could be explanied due to effect of
age and reduction of eGFR and it wasn’t an
independent risk factor.
This part are not in consistent with former study
in which a positive relation between serum
phosphate and sclerostin, regardless GFR, may
have clinical importance(18).
Indeed, Hruska and Mathew (22), by adjusting
serum phosphate via phosphate binders,
inverted CKD-ledd trabecular osteopenia and
so augmented osteoblast surfaces in the
metaphyseal trabeculae of tibia and femur,
osteoid surfaces, and bone formation rates.
Garcia-Martin et al. (23) found that serum
sclerostin significantly correlated with diabetes
duration and glycated hemoglobin in T2DM
patients in disagreement with our study.
Our study showed that there is a positive
correlation between sclerostin with creatinine.
This came in consistent with a cohort
conducted by Kim et al. (12)
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We found that age, urea and ACR were found
to be significantly associated with sclerostin
levels. No significant correlation was revealed
in our study as regarding the effect of gender on
the serum levels of sclerostin.
Modder et al. (16) disagreed with our results as
men had higher circulating sclerostin levels in a
population sample. Kirmani et al. (24)
demonstrated that serum sclerostin levels were
higher in boys aged 6–21 years.
In our study, no significant inverse correlation
was found between BMI and serum sclerostin
levels.
Serum sclerostin negatively correlated with
PTH but not with alkaline phosphatases or
DKK-1 25-26.
This came in opposite to the results by Kim et
al. (12) found that BMI showed negative
correlation with serum sclerostin in all patients,
but it positively correlated with sclerostin in
patients with G1/2..
CONCLUSION
By the end, we concluded that sclerostin level
is negatively correlated with eGFR in diabetic
patients with impaired renal function. Serum
sclerostin levels increase in diabetic patients
starting from CKD-G3 stage. Age, serum
creatinine,
blood
urea,
eGFR
and
albumin/creatinine ratio (ACR) significantly
associated with its level.
This study had some limitations; including
being cross sectional study, relatively small
sample size and lack of control group. Further
large scale prospective studies should be
applied to establish role of serum sclerostin
level.
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